Flexion’s Pandemic Rebound: How Zilretta Dropped 80% But Is Still Coming Out Ahead
The knee osteoarthritis injection was hit hard by COVID-19 restrictions, at first. But CEO Mike Clayman reflected in an interview about how the pandemic experience is helping fuel further growth for Zilretta.
You may also be interested in...
The pharmaceutical selling model will be modified even after the immediate COVID-19 pandemic crisis abates, the consulting firm ZS Associates predicts, citing new research.
Phase III trial presented at ASCO shows 177lutetium-PSMA-617 improved radiographic PFS and OS in advanced prostate cancer patients. Novartis execs say the firm is ready for the marketing challenge.
In Part 2 of Scrip’s roundtable, execs from Athira, Cartesian, Cyclacel, Tonix and VOZ Advisors discuss how the pandemic brought in new investors and triggered strategic shifts for the biopharma industry.